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lease of cytokines and other inflammatory mediators.4
Pressor catecholamines are commonly administered to
support systemic arterial pressure in these cases,5 but
their effectiveness is limited by frequent catecholamine
resistance6 and by significant toxic effects at high
Cardiopulmonary bypass (CPB) can be complicatedby a systemic inflammatory response characterized
by profound vasodilation.1 This vasodilatory shock
syndrome, which is especially noted after extended
CPB,2 is attributed to endothelial injury3 and the re-
Background: Cardiopulmonary bypass can be associated with vasodilatory
hypotension requiring pressor support. We have previously found argi-
nine vasopressin to be a remarkably effective pressor in a variety of
vasodilatory shock states. We investigated the incidence and clinical pre-
dictors of vasodilatory shock in a general population of cardiac surgical
patients and the effects of low-dose arginine vasopressin as treatment of
this syndrome in patients with heart failure. Methods: Patients undergo-
ing cardiopulmonary bypass (n = 145) were studied prospectively.
Preoperative ejection fraction, medications, and perioperative hemody-
namics were recorded, and postbypass serum arginine vasopressin levels
were measured. Vasodilatory shock was defined as a mean arterial pres-
sure lower than 70 mm Hg, a cardiac index greater than 2.5 L/min/m2,
and norepinephrine dependence. Predictors of vasodilatory shock were
investigated by logistic regression analysis. The hemodynamic responses
of patients who received arginine vasopressin infusions for vasodilatory
shock after cardiopulmonary bypass for left ventricular assist device
placement or heart transplantation were analyzed retrospectively.
Results: Eleven of 145 general cardiac surgery patients (8%) met criteria
for postbypass vasodilatory shock. By multivariate analysis, an ejection
fraction lower than 0.35 and angiotensin-converting enzyme inhibitor
use were independent predictors of postbypass vasodilatory shock (rel-
ative risks of 9.1 and 11.9, respectively). Vasodilatory shock was associ-
ated with inappropriately low serum arginine vasopressin concentra-
tions (12.0 ± 6.6 pg/mL). Retrospective analysis found 40 patients with
postbypass vasodilatory shock who received low-dose arginine vaso-
pressin infusions, resulting in increased mean arterial pressure and
decreased norepinephrine requirements. Conclusions: Low ejection frac-
tion and angiotensin-converting enzyme inhibitor use are risk factors
for postbypass vasodilatory shock, and this syndrome is associated with
vasopressin deficiency. In patients exhibiting this syndrome after high-
risk cardiac operations, replacement of arginine vasopressin increases
blood pressure and reduces catecholamine pressor requirements.
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doses.7 Alternative pressor agents could therefore be
useful.
Arginine vasopressin (AVP) has little vasoconstric-
tive effect in hemodynamically normal subjects8 but is
an effective pressor in states associated with arterial
hypotension.9,10 We previously observed a hypersensi-
tivity to the pressor effects of AVP in vasodilatory sep-
tic shock,11 and we recently reported a similar sensitiv-
ity in patients with vasodilatory shock after placement
of left ventricular assist devices (LVADs).12 In most
cases AVP levels on weaning from CPB were inappro-
priately low for the degree of arterial hypotension, and
this finding contrasted with the elevated levels usually
found after CPB.13 On the basis of this experience, we
have used AVP extensively to treat patients with
vasodilatory shock after CPB for LVAD placement and
for heart transplantation (OHT). The general inci-
dence of vasodilatory hypotension and the concordance
with AVP deficiency remains to be defined, as does
the therapeutic role of AVP in the management of this
syndrome.
We therefore undertook this analysis with 2 objec-
tives. First, we sought to prospectively establish in a
general cardiac surgical population the incidence of
vasodilatory shock and the characteristics of this syn-
drome, including presence of AVP deficiency and other
predisposing factors. Second, we retrospectively evalu-
ated our clinical experience with the use of AVP in the
management of vasodilatory hypotension after CPB.
Methods
Study patients and protocols. The prospective study
group consisted of 102 men and 43 women with a mean age
of 61 years. After they provided informed consent, subjects
undergoing elective cardiac surgery were enrolled and were
selected for shock during the first 30 minutes after CPB
weaning on the basis of hypotension (mean arterial pressure
<70 mm Hg) requiring norepinephrine administration for at
least 3 hours. Serum samples were collected for AVP assay
from these patients 5 minutes after weaning from CPB, and
perioperative hemodynamic parameters and exogenous pres-
sor requirements were prospectively recorded. Subjects were
further classified as having cardiogenic shock (cardiac index
<2.5 L/min/m2) or vasodilatory shock (cardiac index >2.5
L/min/m2).
Next a retrospective analysis of LVAD and OHT clinical
databases was performed to find the cases of patients who
had received AVP for the treatment of vasodilatory hypoten-
sion during a 30-month period. Inclusion criteria for this
analysis included post-CPB vasodilatory hypotension
(requirement for exogenous norepinephrine to maintain mean
arterial pressure >70 mm Hg and cardiac index >2.5
L/min/m2) and the administration of AVP. Fourteen LVAD
recipients and 26 OHT recipients met these criteria and
received AVP infusions at a rate of 0.1 U/min. The study
group consisted of 32 men and 8 women, with a mean age of
49.5 years.
Demographic and hemodynamic data for these 40 patients
were obtained for the perioperative period and during the
postoperative intensive care unit stay. The generally applied
protocol for AVP administration was as follows: on identifi-
cation of vasodilatory hypotension and an increasing exoge-
nous pressor requirement, patients received AVP (Pitressin;
Parke-Davis, Morris Plains, NJ) intravenously at a rate of 0.1
U/min. Subsequently catecholamine and then AVP infusions
were tapered to maintain mean arterial pressure above 70 mm
Hg. When hemodynamic improvement allowed discontinua-
tion of catecholamine agents, the AVP infusion rate was pro-
gressively decreased to 0.02 U/min and then discontinued.
Vasopressin assay. Plasma AVP levels were measured by
radioimmunoassay according to published protocols.13
Analysis of data. Hemodynamic and clinical data are
reported as mean ± SD. Continuous variables were analyzed
with the paired and unpaired Student t test and analysis of
variance. The c 2 and Fisher exact tests were applied to dis-
crete variables. Univariable and multivariable logistic regres-
sion analyses were used to determine the relative contribution
of a variety of demographic and clinical factors to the devel-
opment of vasodilatory hypotension. For the multivariable
regression analysis, variables from the univariate analysis
were allowed to enter at the P < .25 level.
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Table I. Demographics of 145 patients undergoing
CPB
Total With VS
Characteristic No. % No. %
Sex
Male 102 70 9 82
Female 43 30 2 18
Operation
Coronary artery bypass 98 59 7 64
Mitral valve replacement 14 8
Aortic valve replacement 17 10 1 9
LVAD 4 3 2 18
OHT 5 3 1 9
Lung transplantation 1 1
Ross procedure 1 1
Atrial septal defect repair 3 2
Aortic aneurysm repair 1 1
Right ventricular resection 1 1
CPB time* (min) 158 ± 59 168 ± 66
Preoperative medications
Diuretics 45 31 7 64
Digoxin 24 17 3 27
ACE inhibitors 31 21 8 73
b -Blockers 49 34 2 18
Calcium-channel blockers 29 20 3 27




Incidence and clinical predictors of postbypass
vasodilatory shock and relationship with plasma
arginine vasopressin levels. Of 145 patients studied
prospectively, 20 (14%) met criteria for post-CPB
hypotension, with 11 cases (8%) meeting criteria for
vasodilatory shock. This low incidence contrasts with
the 42% observed in our earlier study of LVAD recipi-
ents.12 Univariate regression analysis of this data set
examined the variables listed in Table I and found low
ejection fraction (<35%, P < .0001) and the preopera-
tive use of angiotensin-converting enzyme (ACE)
inhibitors (P < .0001) and diuretics (P = .02) to be pre-
dictors of post-CPB vasodilatory shock. A multivariable
logistic regression analysis analyzed a number of fac-
tors (ejection fraction, preoperative diuretics, digoxin,
ACE inhibitors, b -blockers, and calcium-channel block-
ers), and found low ejection fraction (P = .003) and the
use of ACE inhibitors (P = .001) to be independent pre-
dictors of increased risk of post-CPB vasodilatory
shock. The relative risks of post-CPB vasodilatory
shock, as described by odds ratios, were 9.1 (confidence
interval 2.1-38.8) for low ejection fraction and 11.9
(confidence interval 2.7-53.1) for use of ACE inhibitors.
Demographics for this group and for the 11 patients
with vasodilatory shock are summarized in Table I.
The identification of low ejection fraction as a pre-
dictor of vasodilatory shock in our cohort is consistent
with the high incidence of this syndrome previously
reported for our LVAD population (all with low ejec-
tion fraction). In our population of general cardiac sur-
gical patients, 26 of 145 patients (18%) had a low pre-
operative ejection fraction; among these patients there
were 7 cases of vasodilatory shock, corresponding to
The Journal of Thoracic and
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Table II. Hemodynamic characterists and plasma




Post-CPB MAP (mm Hg) 64.6 ± 6.6 68.0 ± 1.2
Cardiac index (L/min/m2) 2.7 ± 0.3 1.9 ± 0.6*
Post-CPB serum AVP (pg/mL) 12.0 ± 6.6 29.3 ± 15.0†
MAP, Mean arterial pressure.
*P = .001.
†P = .004.
Fig 1. Distribution of AVP levels in cardiogenic and vasodilatory shock.
Table III. Demographics of 40 patients receiving AVP
for vasodilatory shock
Characteristic No. %










Ejection fraction <35% 40 100
Timing of AVP infusion
After CPB 33 83
During CPB 7 17
*Mean ± SD.
an incidence of 26.9%, whereas only 4 cases of
vasodilatory shock occurred among 119 patients with
normal ejection fraction (3.3%). Similarly, 30 of 145
patients were receiving preoperative ACE inhibitor
therapy, and vasodilatory shock developed in 8 of these
(26.7%), compared with only 3 of 115 patients (2.6%)
not receiving these agents. The identification of ACE
inhibitor therapy as an independent contributor to the
development of this syndrome underscores the risk in
patients with preoperative heart failure.
The mean post-CPB AVP level in patients with car-
diogenic shock was 29.3 ± 15.0 pg/mL, compared with
12.0 ± 6.6 pg/mL in patients with vasodilatory shock
(P = .004), suggesting that AVP deficiency contributes
to the development of vasodilatory shock. The hemo-
dynamics and AVP levels in these 2 populations are
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Fig 2. Relationship between degree of baseline hypotension and increase in mean arterial pressure (MAP) after
AVP infusion in 40 LVAD and OHT recipients.
Table IV. Hemodynamics before and after administration of AVP, stratified according to degree of initial hypotension
All patients Moderate hypotension Severe hypotension Profound hypotension 
(n = 40) (n = 12) (n = 13) (n = 15)
Before After Before After Before After Before After 
AVP AVP* D AVP AVP* D AVP AVP* D AVP AVP* D
MAP 57.6 ± 81.7 ± 24.2 ± 68.6 ± 86.1 ± 17.5 ± 56.8 ± 78.6 ± 21.7 ± 44.6 ± 79.7 ± 35.1 ±
(mm Hg) 11.0 13.8 15.0 4.2 3.6 11.3 1.9 15.3 15.5 7.3 11.9 13.1†
P <.0001 <.0001 .0003 <.0001
NE 14.4 ± 8.0 ± –6.4 ± 10.3 ± 4.1 ± –6.2 ± 14.0 ± 7.9 ± –6.1 ± 19.8 ± 12.9 ± –7.7 ±
(m g/min) 13.7 10.8 11.6 5.1 5.5 6.7 11.8 8.8 13.2 20.7 15.7 15.2
P .001 .003 .15 .37
SVR 771 ± 1192 ± 400 ± 1018 ± 1169 ± 152 ± 749 ± 1253 ± 413 ± 581 ± 1164 ± 583 ±
(dyne-s/cm5) 304 337 349 242 306 340 223 406 307 269 331 269‡
P <.0001 .24 .005 <.0001
CI 2.9 ± 0.1 2.9 ± 0.1 0 3.0 ± 0.6 2.9 ± 0.3 –0.1 ± 0.6 2.9 ± 0.5 2.9 ± 0.6 0 2.7 ± 0.4 2.8 ± 0.6 0.2 ± 0.6
(L/min/m2)
P 1.0 .64 1.0 .67
MAP, Mean arterial pressure; NE, norepinephrine; SVR, systemic vascular resistance; CI, cardiac index. All values expressed as mean ± SD.
*Values after AVP determined at time of peak blood pressure measurement within 2 hours of AVP administration.
†P < .05 versus severe hypotension and P < .01 versus moderate hypotension (analysis of variance).
‡P < .05 versus moderate hypotension (analysis of variance).
listed in Table II, and the distribution of serum AVP
values is depicted in Fig 1.
Retrospective analysis of therapeutic use of argi-
nine vasopressin in the management of vasodilatory
shock. Twenty-six patients undergoing OHT and 14
receiving LVADs met criteria for post-CPB vasodilato-
ry hypotension during a 30-month evaluation period,
and demographic characteristics of this group are sum-
marized in Table III. AVP infusions were instituted
from 5 minutes to several hours after weaning from
CPB (33 patients) or while the patient was still on CPB
to facilitate weaning (7 patients). Hemodynamic
responses are summarized in Table IV. AVP adminis-
tration resulted in dramatic increases in mean arterial
pressure and systemic vascular resistance. The increas-
es in blood pressure and vascular tone were accompa-
nied by a significant reduction in mean norepinephrine
doses and no appreciable change in cardiac index.
Catecholamine pressors frequently lose their effec-
tiveness in severe vasodilatory shock. In contrast, the
hemodynamic response to AVP infusion was propor-
tional to the severity of vasodilatory hypotension. This
relationship is apparent when patients are divided into
3 groups on the basis of the degree of hypotension
(Figs 2-4, Table IV). After hemodynamic stabilization
(mean arterial pressure >70 mm Hg without exogenous
catecholamine pressor support), AVP was tapered
slowly to 0.01 U/min and then discontinued. In many
cases, initial attempts to discontinue AVP resulted in
significant hypotension, underscoring the importance
of the hormone in the maintenance of vascular tone in
these patients. Duration of AVP infusion ranged
between 1 hour and 6 days. Although a few patients
were rapidly weaned from AVP because hypotension
gave way to significant hypertension, there were no
episodes of malignant hypertension, mesenteric
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Fig 3. Relationship between degree of baseline hypotension and increase in systemic vascular resistance (SVR)
after AVP infusion in 40 LVAD and OHT recipients. MAP, Mean arterial pressure.
Fig 4. Relationship between degree of baseline hypotension
and decrease in norepinephrine (NE) requirements after AVP
infusion in 40 LVAD and OHT recipients. MAP, Mean arterial
pressure.
ischemia, or peripheral ischemia during the postopera-
tive period. There were 3 perioperative deaths, 1 each
from sepsis, hemorrhagic shock, and multisystem
organ failure.
Discussion
CPB with membrane oxygenation is known to induce
a variety of metabolic, hematologic, and neurohumoral
effects, most of which are reversible unless CPB is
excessively prolonged. A common effect is post-CPB
vasoconstriction, which occasionally necessitates
vasodilator administration and is due to temporary ele-
vations in several vasoactive substances, including cat-
echolamines, serotonin, and AVP.14 Patients undergo-
ing aortocoronary bypass operations have been shown
to exhibit increases of more than 6 times in circulating
AVP levels during and as long as 12 hours after CPB,15
to levels often exceeding 100 pg/mL.13 However, a few
authors have documented cases of post-CPB AVP defi-
ciency manifesting as diabetes insipidus,16,17 whereas
others have described a clinical vasodilatory syndrome
responsive to such agents as octreotide18 and
angiotensin II.19
In our study of 145 cardiac surgical patients, the inci-
dence of vasodilatory shock in the early post-CPB peri-
od was 8%, although this syndrome was significantly
more common (27%) among patients with low ejection
fraction. In a previous communication we reported that
this syndrome developed in 42% of patients undergoing
LVAD insertion for end-stage heart failure during a 1-
year period. Perhaps not surprisingly, multivariate
analyses of our study population found low ejection
fraction and use of ACE inhibitors to be independent
predictors of vasodilatory shock. Among the 11
patients with post-CPB vasodilatory shock, most had
AVP levels that, although within the normal osmoregu-
latory range for healthy normotensive subjects (5-15
pg/mL),20 were inappropriately low for the degree of
arterial hypotension that was present (≤15 pg/mL).
The mechanisms contributing to AVP deficiency in
this syndrome are a matter of speculation. Hypo-
natremia can blunt the AVP response to baroreflex-
mediated stimuli,21 but serum sodium levels were nor-
mal (136.2 ± 1.7 mEq/L) in our patients. Similarly,
activation of atrial stretch receptors is known to inhibit
AVP release through vagal afferent pathways,22 but
central venous pressure was not elevated (12.0 ± 1.2
mm Hg) during the period of hypotension in our
patients. Nonetheless, potential neurohumoral effects
of preoperative elevations in cardiac filling pressures
cannot be excluded. Atrial natriuretic peptide (ANP)
could be responsible for AVP deficiency because it is
also known to inhibit AVP secretion, and the serum lev-
els of ANP are often increased after CPB.23 Finally,
autonomic dysfunction could contribute because it is
associated with AVP deficiency and has been docu-
mented in patients with heart failure.24
The dose of AVP administered to our patients under-
going LVAD implantation and OHT, 0.1 U/min, is
between a fourth and a ninth that administered to
patients with cirrhosis for the control of bleeding
esophageal varices. This dose provides a steady-state
plasma concentration of at least 150 pg/mL,25 compa-
rable to levels previously reported after CPB. LVAD
and OHT recipients with vasodilatory shock proved to
be extremely sensitive to this dose of AVP, with rapid
hemodynamic responses even in the absence of a load-
ing dose. In several cases the AVP dose was decreased
to 0.01 U/min, which was sufficient to maintain blood
pressure without catecholamine pressors. This dose
corresponds to a plasma concentration of less than 40
pg/mL25 (similar to AVP levels observed in our patients
in cardiogenic shock) and could therefore constitute
physiologic replacement.
The mechanisms by which AVP acts as a pressor in
patients resistant to catecholamines are not clear, but a
number of intriguing possibilities exist. Vasodilatory
shock after CPB is likely due to pathologic activation
of several vasodilator mechanisms. The interleukin 1
level is elevated in inflammatory states and ANP is
increased after CPB, and both promote vasodilation
through increased levels of intracellular cyclic guano-
sine monophosphate.26,27 Also, adenosine triphos-
phate–activated potassium channels of vascular smooth
muscle are activated by tissue hypoxia and hypoperfu-
sion (and presumably by CPB), and this activation
causes vasodilation by inducing cellular hyperpolariza-
tion and inhibiting voltage-gated calcium channels.28
Both catecholamines and AVP effect vasoconstriction
by increasing intracellular calcium levels in vascular
smooth muscle through activation of voltage-gated cal-
cium channels, and the activation of vasodilator path-
ways could impair this calcium-dependent mechanism.
In contrast to catecholamines, however, AVP also in-
hibits the production of cyclic guanosine monophos-
phate by interleukin 1 and by ANP29,30 and inhibits the
adenosine triphosphate–activated potassium channels
of vascular smooth muscle.28 Thus the efficacy of AVP
as a pressor in a variety of clinical scenarios in which
catecholamines are ineffective may rest on its ability to
specifically counteract pathologically activated vaso-
dilatory mechanisms. This hypothesis may also explain
the restoration of catecholamine sensitivity that we
have frequently observed after AVP administration.
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We found in our prospective study that vasodilatory
shock after CPB is associated with AVP deficiency and
that this syndrome is more common among patients
with low ejection fraction and those receiving ACE
inhibitors. We also retrospectively observed, in a large
number of patients undergoing LVAD implantation and
OHT, that AVP is an effective pressor in the setting of
post-CPB vasodilation, significantly increasing mean
arterial pressure while reducing the requirement for cat-
echolamine pressor agents. All patients in vasodilatory
shock responded to AVP administration, and the magni-
tude of the hemodynamic response was proportional to
the severity of hypotension at the time of infusion initi-
ation. Our results are preliminary, and a large-scale con-
trolled trial of AVP for the treatment of vasodilatory
shock after CPB will be required to determine the risks
and benefits associated with the use of this novel agent
in the management of cardiac surgical patients.
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Discussion
Dr Richard D. Weisel (Toronto, Ontario, Canada). The
problem is important. We have all seen patients who are pro-
foundly hypotensive after operation, but we seldom know
why and our treatment is far from adequate. As you do, we
give them pressor agents, and we are always afraid that the
arterial grafts are going to go into spasm. Occasionally they
do. This is a major concern.
You have previously published information about patients
undergoing LVAD implantation and OHT. I think we can
understand why these patients are perhaps a little bit differ-
ent. Both populations have unique features that are going to
make them more susceptible to this. Could you perhaps pick
out for us, though, the patients who are not LVAD or OHT
recipients and see whether in fact the same process is going
on in these other patients—particularly those undergoing
coronary bypass, who comprise the majority of the elective
cardiac surgical patients?
How many patients undergoing general cardiac surgery
actually had vasodilatory shock, and how many of those had
low AVP levels? Did all patients with vasodilatory shock
respond the same, whether or not their AVP levels were low
to begin with? I wonder whether you could clarify this for me.
Otherwise I think that it is a great idea. If we can get spe-
cific information, we will probably have a more specific ther-
apy for this disturbing complication after heart operations.
Dr Argenziano. Although we first noticed this phenome-
non in LVAD recipients and then directed our attention to
OHT recipients, we have also asked ourselves the question,
“Is this a relevant syndrome in general cardiac surgery?” That
question is really what prompted the prospective trial that we
presented here today.
In this prospective trial of 145 patients there were only 4
LVAD and 5 OHT recipients. We performed a separate statis-
tical analysis in which we pulled those patients out. Even
after removing the LVAD and OHT recipients from that pop-
ulation of 145, we found the same statistical significance with
respect to ejection fraction and ACE inhibitor therapy as pre-
dictors of this syndrome.
With respect to the number of patients in whom the syn-
drome developed, there were actually 11 patients in whom
vasodilatory shock occurred among the 145 at whom we
looked prospectively. Only 1 of those was an OHT recipient
and 2 were LVAD recipients. So, after removal of the LVAD
and OHT recipients there were 8 patients among 136 in whom
this complication developed. Thus vasodilatory shock is a
complication that occurred in 6% or 7% of the general cardiac
surgical patients whom we studied, excluding the patients
undergoing LVAD implantation and OHT. AVP levels were
obtained for all these patients and, as I described in my pre-
sentation, the AVP levels were inappropriately low in all but 1
of the patients who had vasodilatory shock. All the levels were
below 20 pg/mL except 1 that was about 23 pg/mL.
The AVP levels that we expect in patients who are pro-
foundly hypotensive are in the 40 to 50 pg/mL range, and
they range as high as 100 pg/mL in some reports. All our
patients who were in profound vasodilatory shock therefore
had grossly deficient secretion of AVP.
With respect to whether all patients responded similarly to
AVP, we tried to analyze this by separating patients into 3
groups according to the degree of hypotension. All patients
responded, but some responded more than others. If the mean
arterial pressure is 65 mm Hg and AVP is administered, the
pressure rises to 80 mm Hg. If the mean arterial pressure is
45 mm Hg and AVP is administered, the pressure rises to 80
mm Hg. So you might say, “Why give AVP to patients whose
mean arterial pressure is 65 mm Hg?” That is a good point.
You may not want to give it to those patients. You may instead
want to give those patients a little norepinephrine. You should
know, however, that in our opinion this hormone seems to act
as a replacement therapy for some deficiency, rather than as
an exogenous pressor. We do not titrate it to increasing doses.
We do not give more AVP when we want a higher blood pres-
sure. We just give a single dose, and it seems to be effective
in most cases.
Dr Karl H. Krieger (New York, NY). These are really com-
pelling data. In your current practice, if you have a patient at
high risk, for example a patient with poor ejection fraction
who has been receiving ACE inhibitors and diuretics, might
you give AVP prophylactically? Is there any contraindication
to giving AVP; have you had any problems with it?
Dr Argenziano. That is a good question. Certainly, as you
might imagine, AVP is now stocked in both our intensive care
units and operating rooms. We use it quite frequently. We
have not yet, however, given it prophylactically to patients
who are not hypotensive. We have reserved it for patients
with demonstrated need. It must be remembered that we are
using AVP to treat vasodilatory shock. Most patients in hemo-
dynamically unstable condition before a cardiac operation are
not in vasodilatory shock but rather in cardiogenic shock, in
which the vascular tone is actually quite high. We would not
expect AVP to have an effect in those cases, because it is not
an inotrope but rather a pure vasoconstrictor. We generally
reserve AVP for patients in whom vasodilatory shock devel-
ops after CPB, but we certainly have used it in a few cases in
which this syndrome developed before the operation.
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